A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

NCT05111509 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumor Grade 2
Neuroendocrine Tumor Grade 1

Interventions

DRUG: [203Pb]VMT-α-NET
DEVICE: SPECT/CT

Sponsor

Yusuf Menda

Collaborators

[object Object]
[object Object]
[object Object]